Dabigatran and the real world
Just published in JACC, the Danish observational study that examined dabigatran vs warfarin use reports encouraging
"real-world" results for the first novel oral coagulant approved for the prevention of stroke in AF. (Source: Blogs@theHeart.org)
Source: Blogs@theHeart.org - April 15, 2013 Category: Cardiology Authors: theheart.org Tags: Clotblog with Dr Samuel Goldhaber Source Type: blogs
Registry Study Offers Reassurance About Safety And Efficacy Of Dabigatran
As the first new oral anticoagulant since warfarin, dabigatran (Pradaxa, Boehringer-Ingelheim) has been subject to intense concerns over its safety and efficacy in a real-world population. Last November an FDA investigation found no indication that bleeding rates for dabigatran were any higher than bleeding rates for warfarin. A new study from Scandinavia, published in the Journal of the American College of Cardiology (see note at bottom of story), provides more real-world information that helps to confirm the safety and efficacy of the new drug. Using data from the Danish Registry of Medicinal Product Statistics, re...
Source: CardioBrief - April 4, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Prevention, Epidemiology & Outcomes anticoagulants boehringer ingelheim dabigatran Pradaxa warfarin Source Type: blogs
What to do about bridging with novel oral anticoagulants with Dr Seth Bilazarian
Sharing a rare moment of person-to-person time during the scientific sessions in San Francisco, Dr Seth Bilazarian asks Drs Samuel Goldhaber how he goes about bridging with dabigatran, rivaroxaban, and apixaban. (Source: Blogs@theHeart.org)
Source: Blogs@theHeart.org - March 28, 2013 Category: Cardiology Authors: theheart.org Tags: Clotblog with Dr Samuel Goldhaber Source Type: blogs
#183: Mixed messages on new bleeding data with dabigatran; "high-potency" statins linked to acute kidney injury; dabigatran might cut hospital days vs standard anticoagulants in new AF; US supermarket chain giving away atorvastatin
Mixed messages on new bleeding data with dabigatran; "high-potency" statins linked to acute kidney injury; dabigatran might cut hospital days vs standard anticoagulants in new AF; US supermarket chain giving away atorvastatin (Source: Blogs@theHeart.org)
Source: Blogs@theHeart.org - March 22, 2013 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: blogs
FDA Officials Calm Concerns Over Excessive Bleeding With Dabigatran
Concerns over excessive bleeding complications with dabigatran (Pradaxa, Boehringer Ingelheim) as compared with warfarin are most likely due to the heightened sensitivity and vigilance that can accompany a new drug, according to FDA officials in a perspective published online in the New England Journal of Medicine. “We believe that the large number of reported cases of bleeding associated with dabigatran provides a salient example of stimulated reporting,” write Mary Ross Southworth, Marsha Reichman, and Ellis Unger. “In this case, such reporting provided a distorted estimate of the comparative bleeding r...
Source: CardioBrief - March 13, 2013 Category: Cardiology Authors: Larry Husten Tags: Heart Rhythms Policy & Ethics Prevention, Epidemiology & Outcomes anticoagulants boehringer ingelheim dabigatran FDA new england journal of medicine Pradaxa warfarin Source Type: blogs
Is it safe to take aspirin and warfarin together?
The ultimate goal in medicine: protect the patient from stroke. Even a heart doctor has to admit the dominance of the human brain.
Always think about preventing stroke. It’s one of the worst outcomes that can happen to a person. Life as a ‘normal’ human requires a healthy brain. A stroke irreversibly kills off part of the brain. Stuff you take for granted can go away: swallowing, speaking, understanding language, sight, movement of a limb, not drooling, and the list goes on.
The most common cause of stroke is ischemic–meaning a blocked blood vessel leading to the brain or in the brain itself. A comm...
Source: Dr John M - March 7, 2013 Category: Cardiology Authors: Dr John Source Type: blogs
What's Missing in Scientific Journal Articles on New Innovations in Medicine
My perspective on scientific publications has been greatly affected by my experience with this blog and social media in particular. The ability to serve as author, reviewer, advertiser and marketer can be easily achieved in this space thanks to the power of self-publishing. But with this new platform comes new responsibilities and for those of us who chose to work with people daily, perhaps (Source: Dr. Wes)
Source: Dr. Wes - March 5, 2013 Category: Cardiology Authors: Westby G. Fisher, MD Tags: dabigatran apixaban pharmaceutical industry transparency rivaroxaban Source Type: blogs
New Studies Examine Prolonged Anticoagulation For VTE Recurrence
Three studies published in the New England Journal of Medicine provide important new information about the risks and benefits of extended prophylaxis using two of the new oral anticoagulants in patients who have had venous thromboembolism (VTE). … In an accompanying editorial, Jean Connors writes that “deciding how to balance the risks and benefits of extended anticoagulation is difficult” in patients with unprovoked VTE, since the risk of recurrent VTE may reach 40% at 5 years. Patients at low-to-moderate risk of recurrence may benefit from aspirin, which “may be safer than the newer agents,R...
Source: CardioBrief - February 20, 2013 Category: Cardiology Authors: Larry Husten Tags: Prevention, Epidemiology & Outcomes anticoagulation apixaban dabigatran Eliquis new england journal of medicine rivaroxaban venous thromboembolism VTE warfarin Source Type: blogs
When you patient on pradaxa bleeds
(Source: Notes from Dr. RW)
Source: Notes from Dr. RW - January 28, 2013 Category: Internists and Doctors of Medicine Tags: toxicology hematology cardiovascular Source Type: blogs
